Humana Inc. $HUM Shares Sold by BI Asset Management Fondsmaeglerselskab A S

BI Asset Management Fondsmaeglerselskab A S decreased its position in Humana Inc. (NYSE:HUM) by 33.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,144 shares of the insurance provider’s stock after selling 2,107 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S’s holdings in Humana were worth $719,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Capital International Investors lifted its holdings in Humana by 113.9% in the 4th quarter. Capital International Investors now owns 5,818,008 shares of the insurance provider’s stock valued at $1,490,239,000 after acquiring an additional 3,097,571 shares during the last quarter. Norges Bank bought a new stake in shares of Humana in the 4th quarter worth approximately $456,632,000. Wellington Management Group LLP raised its holdings in shares of Humana by 4,481.7% in the 4th quarter. Wellington Management Group LLP now owns 1,196,502 shares of the insurance provider’s stock worth $306,460,000 after purchasing an additional 1,170,387 shares in the last quarter. Franklin Resources Inc. lifted its stake in Humana by 914.5% during the fourth quarter. Franklin Resources Inc. now owns 1,255,665 shares of the insurance provider’s stock valued at $321,613,000 after purchasing an additional 1,131,893 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its stake in Humana by 28.9% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,496,775 shares of the insurance provider’s stock valued at $1,151,759,000 after purchasing an additional 1,008,514 shares during the last quarter. Institutional investors own 92.38% of the company’s stock.

Humana Stock Performance

Shares of HUM opened at $375.45 on Friday. The firm has a market cap of $45.08 billion, a price-to-earnings ratio of 40.16, a price-to-earnings-growth ratio of 2.06 and a beta of 0.76. The company’s fifty day moving average is $299.39 and its 200-day moving average is $244.75. The company has a quick ratio of 1.77, a current ratio of 1.77 and a debt-to-equity ratio of 0.66. Humana Inc. has a 12 month low of $163.11 and a 12 month high of $380.86.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, April 29th. The insurance provider reported $10.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $9.97 by $0.34. The business had revenue of $39.65 billion during the quarter, compared to analyst estimates of $39.37 billion. Humana had a net margin of 0.82% and a return on equity of 10.45%. Humana’s quarterly revenue was up 23.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $11.58 EPS. Humana has set its FY 2026 guidance at 9.000- EPS. Equities analysts expect that Humana Inc. will post 9.04 EPS for the current fiscal year.

Humana Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Friday, June 26th will be issued a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, June 26th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 0.9%. Humana’s dividend payout ratio is currently 37.86%.

Wall Street Analyst Weigh In

Several research analysts have issued reports on HUM shares. Sanford C. Bernstein restated an “outperform” rating and issued a $425.00 price target on shares of Humana in a research report on Wednesday, June 3rd. JPMorgan Chase & Co. raised their price objective on Humana from $214.00 to $316.00 and gave the stock a “neutral” rating in a research note on Monday, June 8th. Seaport Research Partners cut Humana to a “neutral” rating in a report on Wednesday, May 20th. Deutsche Bank Aktiengesellschaft lowered Humana from a “buy” rating to a “hold” rating in a research report on Wednesday, May 20th. Finally, Bank of America increased their price target on Humana from $340.00 to $380.00 and gave the company a “neutral” rating in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, sixteen have issued a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $293.09.

About Humana

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.